|Over a week ago|
AGTC completes enrollment in highest dose groups of Phase 1/2 trial of AGTC-501 » 07:0402/1902/19/20
Applied Genetic Technologies announced that it has completed enrollment in the two highest dose groups of its Phase 1/2 clinical trial evaluating the safety and efficacy of sub-retinal injection of AGTC-501 for the treatment of X-linked retinitis pigmentosa caused by mutations in the RPGR gene. The patients in these additional groups received a higher or highest dose of AGTC's XLRP candidate.
Applied Genetic in position to execute after cash raise, says Roth Capital » 12:1002/1202/12/20
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah said 2019 "was a good year" for Applied Genetic Technologies that has been followed by a strong start in 2020 with positive 6-month interim data for XLRP announced in January. A recent cash raise positions Applied "to fully execute on all fronts," contends Jallah, who remains bullish on the stock as she looks forward to updated results from the company's two lead programs before year-end. Jallah has a Buy rating on Applied Genetic Technologies shares.
Applied Genetic 6.5M share Spot Secondary priced at $5.00 » 20:0702/0602/06/20
The deal size was…
The deal size was increased from 6.0M shares and priced below the last closing price of $5.71. Wells Fargo and Wedbush are acting as joint book running managers for the offering.
Fly Intel: After Hours Movers » 19:0002/0502/05/20
RAMP, SONO, ELF, ACLS, ARWR, CURO, QNST, ZNGA, GLUU, CENTA, FORM, IRBT, NUAN, COHR, CSGS, FOXA, ENSG, SAVE, FLO, LNC, CTSH, GPRO, ENS, ANGI, UHAL, CDAY, PTON, TWO, TWLO, PAYC, FEYE, NTGR, YUMC, MXL, GRUB, ICHR, QCOM, IAC, MET, FNKO, AGTC
UP AFTER EARNINGS:…
UP AFTER EARNINGS: LiveRamp (RAMP) up 10.4%... Sonos (SONO) up 9.9%... e.l.f. Beauty (ELF) up 8.7%... Axcelis Technologies (ACLS) up 7.2%... Arrowhead Pharma (ARWR) up 6.7%... Curo Group (CURO) up 6.2%... QuinStreet (QNST) up 6.2%... Zynga (ZNGA) up 5.2%... Glu Mobile (GLUU) up 4.5%... Central Garden & Pet (CENTA) up 4.3%... FormFactor (FORM) up 4.3%... Nuance Communications (NUAN) up 4.0%... Coherent (COHR) up 3.7%... CSG Systems (CSGS) up 3.4%... iRobot (IRBT) up 3.4%... Ensign Group (ENSG) up 3.3%... Fox Corp (FOXA) up 3.2%... Spirit Airlines (SAVE) up 2.4%... Flowers Foods (FLO) up 2.2%... Lincoln National (LNC) up 2.0%... Cognizant (CTSH) up 1.6%... DOWN AFTER EARNINGS: GoPro (GPRO) down 13.5%... EnerSys (ENS) down 12.9%... Angi Homeservices (ANGI) down 10.7%... Amerco (UHAL) down 10.3%... Ceridian HCM (CDAY) down 9.2%... Peloton (PTON) down 8.0%... Two Harbors (TWO) down 5.0%... Twilio (TWLO) down 4.7%... PayCom (PAYC) down 4.6%... FireEye (FEYE) down 4.5%... NetGear (NTGR) down 3.6%... Yum China (YUMC) down 3.0%... MaxLinear (MXL) down 2.6%... GrubHub (GRUB) down 2.0%... Ichor Holdings (ICHR) down 1.9%... Qualcomm (QCOM) down 1.8%... IAC (IAC) down 1.8%... MetLife (MET) down 1.6%. ALSO LOWER: Funko (FNKO) down 36.0% after below-consensus preliminary Q4 outlook... ION Geophysical Corp (IO) down 20.6%... Applied Genetic Technologies (AGTC) down 8.7% after equity offering... Movers as of 18:15ET.
Applied Genetic files to sell 6M shares of common stock » 16:3802/0502/05/20
Wells Fargo Securities,…
Wells Fargo Securities, LLC and Wedbush Securities Inc. are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering. Janney Montgomery Scott LLC and Roth Capital Partners are acting as co-managers for the offering.
Applied Genetic files to offer 6M shares of common stock » 16:3802/0502/05/20
Wells Fargo Securities,…
Wells Fargo Securities, LLC and Wedbush Securities Inc. are acting as joint book-running managers for the offering.
|Over a month ago|
Applied Genetic files to sell $35M in common stock 17:3101/2901/29/20
Fly Intel: Top five analyst initiations » 10:1301/2801/28/20
UBER, INSP, AGTC, POR, WWE
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with a Buy at UBS. 2. Inspire Medical (INSP) initiated with an Underperform at Oppenheimer. 3. Applied Genetic (AGTC) initiated with a Buy at Roth Capital. 4. Portland General Electric (POR) initiated with a Sector Weight at KeyBanc. 5. WWE (WWE) initiated with a Buy at Northcoast. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Otonomy presents preclinical results for GJB2 collaboration, cisplatin program » 07:3201/2801/28/20
Otonomy (OTIC) announced…
Otonomy (OTIC) announced preclinical results from the company's gene therapy collaboration with Applied Genetic Technologies Corporation (AGTC) focused initially on treating GJB2 deficiency for congenital hearing loss, and preclinical results demonstrating the therapeutic potential of a class of compounds being evaluated for otoprotection against cisplatin-induced hearing loss. These results were presented during the ongoing Association for Research in Otolaryngology 43rd Annual MidWinter Meeting being held in San Jose, California. In October 2019, Otonomy and AGTC announced a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction protein beta 2 gene -- the most common cause of congenital hearing loss. The joint presentation by Otonomy and AGTC at ARO provided initial demonstration that a gene of interest can be expressed in support cells of the cochlea, which are the relevant target cells for treating GJB2 deficiency, using novel and proprietary AAV capsids. Furthermore, these studies identified several capsids with favorable tropism and gene expression level in support cells compared to previously reported capsids used in the field. Importantly, none of the novel AAV capsids evaluated for further development exhibited signs of cellular toxicity. Cisplatin is a potent chemotherapeutic agent that is widely used to treat a variety of cancers in adults and children. Unfortunately, the administration of cisplatin is commonly associated with severe adverse effects including CIHL that is progressive, bilateral and irreversible. At ARO, Otonomy presented preclinical results demonstrating varying degrees of otoprotection against CIHL for several different classes of therapeutic agents. In particular, a novel proprietary class of agents that potently bind to cisplatin demonstrated greater otoprotection than anti-oxidant and anti-apoptotic molecules, and increased potency relative to other cisplatin-binding molecules currently in clinical development. These results highlight the therapeutic potential of Otonomy's novel otoprotectant agents as the basis for the OTO-510 program for CIHL.
Applied Genetic to host R&D Day » 06:5501/2801/28/20
R&D Day to be held in…
R&D Day to be held in New York on January 28 at 7:30 am. Webcast Link